{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:03:11Z","timestamp":1777420991801,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T00:00:00Z","timestamp":1446595200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s10552-015-0687-0","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T07:56:47Z","timestamp":1446623807000},"page":"105-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Metformin and prostate cancer mortality: a meta-analysis"],"prefix":"10.1007","volume":"27","author":[{"given":"Konrad H.","family":"Stopsack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Ziehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward L.","family":"Giovannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,4]]},"reference":[{"key":"687_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69\u201390","journal-title":"CA Cancer J Clin"},{"key":"687_CR2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10552-012-9946-5","volume":"23","author":"B Attner","year":"2012","unstructured":"Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H (2012) Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control 23:769\u2013777","journal-title":"Cancer Causes Control"},{"key":"687_CR3","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1055-9965.EPI-06-0410","volume":"15","author":"JS Kasper","year":"2006","unstructured":"Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 15:2056\u20132062","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"687_CR4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10552-013-0334-6","volume":"25","author":"L Bensimon","year":"2014","unstructured":"Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L (2014) Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25:329\u2013338","journal-title":"Cancer Causes Control"},{"key":"687_CR5","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","volume":"29","author":"DM Nathan","year":"2006","unstructured":"Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963\u20131972","journal-title":"Diabetes Care"},{"key":"687_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.2809","volume":"223","author":"R Flavin","year":"2011","unstructured":"Flavin R, Zadra G, Loda M (2011) Metabolic alterations and targeted therapies in prostate cancer. J Pathol 223:283\u2013294","journal-title":"J Pathol"},{"key":"687_CR7","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","volume":"27","author":"I Ben Sahra","year":"2008","unstructured":"Ben Sahra I, Laurent K, Loubat A et al (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576\u20133586","journal-title":"Oncogene"},{"key":"687_CR8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","volume":"3","author":"A DeCensi","year":"2010","unstructured":"DeCensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3:1451\u20131461","journal-title":"Cancer Prev Res (Phila)"},{"key":"687_CR9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.canep.2012.12.009","volume":"37","author":"P Zhang","year":"2013","unstructured":"Zhang P, Li H, Tan X, Chen L, Wang S (2013) Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 37:207\u2013218","journal-title":"Cancer Epidemiol"},{"key":"687_CR10","doi-asserted-by":"crossref","first-page":"e116327","DOI":"10.1371\/journal.pone.0116327","volume":"9","author":"H Yu","year":"2014","unstructured":"Yu H, Yin L, Jiang X et al (2014) Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS ONE 9:e116327","journal-title":"PLoS ONE"},{"key":"687_CR11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2014.52","volume":"18","author":"AD Raval","year":"2015","unstructured":"Raval AD, Thakker D, Vyas A, Salkini M, Madhavan S, Sambamoorthi U (2015) Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 18:110\u2013121","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"687_CR12","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"687_CR13","doi-asserted-by":"crossref","unstructured":"Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D (2005) Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 20(3):CD002966","DOI":"10.1002\/14651858.CD002966.pub3"},{"key":"687_CR14","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","volume":"24","author":"AJ Stephenson","year":"2006","unstructured":"Stephenson AJ, Kattan MW, Eastham JA et al (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24:3973\u20133978","journal-title":"J Clin Oncol"},{"key":"687_CR15","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","volume":"31","author":"D Margel","year":"2013","unstructured":"Margel D, Urbach DR, Lipscombe LL et al (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069\u20133075","journal-title":"J Clin Oncol"},{"key":"687_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101\u2013129","journal-title":"Biometrics"},{"key":"687_CR17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"687_CR18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","volume":"323","author":"P J\u00fcni","year":"2001","unstructured":"J\u00fcni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42\u201346","journal-title":"BMJ"},{"key":"687_CR19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"687_CR20","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1055-9965.EPI-14-0056","volume":"23","author":"L Bensimon","year":"2014","unstructured":"Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L (2014) The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomark Prev 23:2111\u20132118","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"687_CR21","doi-asserted-by":"crossref","unstructured":"Xu H, Aldrich MC, Chen Q et al (2015) Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc 22(1):179\u2013191","DOI":"10.1136\/amiajnl-2014-002649"},{"key":"687_CR22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2012.12.004","volume":"63","author":"DE Spratt","year":"2013","unstructured":"Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ (2013) Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 63:709\u2013716","journal-title":"Eur Urol"},{"key":"687_CR23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/EDE.0000000000000174","volume":"25","author":"C H\u00e4ggstr\u00f6m","year":"2014","unstructured":"H\u00e4ggstr\u00f6m C, Stocks T, Nagel G et al (2014) Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology 25:823\u2013828","journal-title":"Epidemiology"},{"key":"687_CR24","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE L\u00e9vesque","year":"2010","unstructured":"L\u00e9vesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087","journal-title":"BMJ"},{"key":"687_CR25","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1093\/annonc\/mdr020","volume":"22","author":"XX He","year":"2011","unstructured":"He XX, Tu SM, Lee MH, Yeung SC (2011) Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22:2640\u20132645","journal-title":"Ann Oncol"},{"key":"687_CR26","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.urology.2010.03.059","volume":"76","author":"T Patel","year":"2010","unstructured":"Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM (2010) Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76:1240\u20131244","journal-title":"Urology"},{"key":"687_CR27","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1097\/01.ju.0000049200.30192.d1","volume":"169","author":"AV D\u2019Amico","year":"2003","unstructured":"D\u2019Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH (2003) Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 169:1320\u20131324","journal-title":"J Urol"},{"key":"687_CR28","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djt170","volume":"105","author":"D Margel","year":"2013","unstructured":"Margel D, Urbach D, Lipscombe LL et al (2013) Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 105:1123\u20131131","journal-title":"J Natl Cancer Inst"},{"key":"687_CR29","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1200\/JCO.2013.50.7715","volume":"31","author":"KL Penney","year":"2013","unstructured":"Penney KL, Stampfer MJ (2013) The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol 31:3054\u20133055","journal-title":"J Clin Oncol"},{"key":"687_CR30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2012.10.002","volume":"63","author":"M Popiolek","year":"2013","unstructured":"Popiolek M, Rider JR, Andren O et al (2013) Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 63:428\u2013435","journal-title":"Eur Urol"},{"key":"687_CR31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-015-0280-1","volume":"38","author":"E Patorno","year":"2015","unstructured":"Patorno E, Garry EM, Patrick AR et al (2015) Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review. Drug Saf 38:295\u2013310","journal-title":"Drug Saf"},{"key":"687_CR32","first-page":"335","volume":"7","author":"AM Walker","year":"1996","unstructured":"Walker AM (1996) Confounding by indication. Epidemiology 7:335\u2013336","journal-title":"Epidemiology"},{"key":"687_CR33","doi-asserted-by":"crossref","first-page":"e0124761","DOI":"10.1371\/journal.pone.0124761","volume":"10","author":"H Lee","year":"2015","unstructured":"Lee H, Kuk H, Byun SS, Lee SE, Hong SK (2015) Preoperative glycemic control status as a significant predictor of biochemical recurrence in prostate cancer patients after radical prostatectomy. PLoS ONE 10:e0124761","journal-title":"PLoS ONE"},{"key":"687_CR34","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","volume":"35","author":"S Suissa","year":"2012","unstructured":"Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665\u20132673","journal-title":"Diabetes Care"},{"key":"687_CR35","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915\u2013920","journal-title":"Am J Epidemiol"},{"key":"687_CR36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF (2014) The Hartung\u2013Knapp\u2013Sidik\u2013Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian\u2013Laird method. BMC Med Res Methodol 14:25","journal-title":"BMC Med Res Methodol"},{"key":"687_CR37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2013.12.057","volume":"66","author":"C Rothermundt","year":"2014","unstructured":"Rothermundt C, Hayoz S, Templeton AJ et al (2014) Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08\/09). Eur Urol 66:468\u2013474","journal-title":"Eur Urol"},{"key":"687_CR38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/pcan.2014.20","volume":"17","author":"AM Joshua","year":"2014","unstructured":"Joshua AM, Zannella VE, Downes MR et al (2014) A pilot \u2018window of opportunity\u2019 neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17:252\u2013258","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"687_CR39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/pcan.2013.48","volume":"16","author":"EH Allott","year":"2013","unstructured":"Allott EH, Abern MR, Gerber L et al (2013) Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 16:391\u2013397","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"43","key":"687_CR40","first-page":"e1","volume":"32","author":"D Kaushik","year":"2014","unstructured":"Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ (2014) Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 32(43):e1\u2013e7","journal-title":"Urol Oncol"},{"key":"687_CR41","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.eururo.2013.04.015","volume":"64","author":"DE Spratt","year":"2013","unstructured":"Spratt DE, Zhang Z, Zelefsky MJ (2013) Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay\u2019s letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709\u201316. Eur Urol 64:e29\u2013e30","journal-title":"Eur Urol"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-015-0687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-015-0687-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-015-0687-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T04:04:08Z","timestamp":1653451448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-015-0687-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,4]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s10552-015-0687-0","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,4]]}}}